139 related articles for article (PubMed ID: 19734947)
1. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation.
Rumi E; Passamonti F; Arcaini L; Bernasconi P; Elena C; Pietra D; Brisci A; Arbustini E; Cazzola M; Lazzarino M
Bone Marrow Transplant; 2010 Apr; 45(4):798-800. PubMed ID: 19734947
[No Abstract] [Full Text] [Related]
2. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H; Badbaran A; Bock O; Fehse B; Bacher U; Zander AR; Kröger N
Bone Marrow Transplant; 2010 Sep; 45(9):1404-7. PubMed ID: 20062088
[TBL] [Abstract][Full Text] [Related]
3. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
4. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
5. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
6. [Treatment strategy for myeloproliferative neoplasms].
Yoshimoto G; Miyamoto T
Rinsho Ketsueki; 2014 Oct; 55(10):1841-52. PubMed ID: 25297748
[No Abstract] [Full Text] [Related]
7. Detection of MPL mutations by a novel allele-specific PCR-based strategy.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Nov; 15(6):810-8. PubMed ID: 23994117
[TBL] [Abstract][Full Text] [Related]
8. MPL-mutated essential thrombocythemia: a morphologic reappraisal.
Szuber N; Hanson CA; Lasho TL; Finke C; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2018 Nov; 8(12):121. PubMed ID: 30459342
[No Abstract] [Full Text] [Related]
9. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.
Haider M; Elala YC; Gangat N; Hanson CA; Tefferi A
Blood Cancer J; 2016 Oct; 6(10):e487. PubMed ID: 27768091
[No Abstract] [Full Text] [Related]
10. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
11. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
Guglielmelli P; Pancrazzi A; Bergamaschi G; Rosti V; Villani L; Antonioli E; Bosi A; Barosi G; Vannucchi AM; ;
Br J Haematol; 2007 May; 137(3):244-7. PubMed ID: 17408465
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract][Full Text] [Related]
13. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
15. Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
Torka P; Hahn T; Bertolo J; Liu H; Ross M; Paplham P; Jankowski A; Deeb G; Chen G; McCarthy P
Bone Marrow Transplant; 2015 Nov; 50(11):1480-2. PubMed ID: 26214139
[No Abstract] [Full Text] [Related]
16. Impact of molecular residual disease post allografting in myelofibrosis patients.
Wolschke C; Badbaran A; Zabelina T; Christopeit M; Ayuk F; Triviai I; Zander A; Alchalby H; Bacher U; Fehse B; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1526-1529. PubMed ID: 28714945
[TBL] [Abstract][Full Text] [Related]
17. Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay.
Laurent C; Demas V; Delabesse E; Brousset P
Hum Pathol; 2007 Oct; 38(10):1581-2. PubMed ID: 17889678
[No Abstract] [Full Text] [Related]
18. [Molecular pathophysiology and treatment overview of PV, ET and PMF].
Komatsu N
Rinsho Ketsueki; 2012 Oct; 53(10):1589-99. PubMed ID: 23037731
[No Abstract] [Full Text] [Related]
19. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
[TBL] [Abstract][Full Text] [Related]
20. Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis.
Chua CC; Omerod A; Wight J; Juneja S; Zantomio D
Pathology; 2018 Oct; 50(6):671-674. PubMed ID: 30097170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
